Development of EEG Biomarkers to Assist Treatment Development in Fragile X Syndrome

On seeking measurable parameters to quantify treatment effects on brain circuits in Fragile X syndrome.

↓ SIGN UP, IT’S FREE!   And you’ll be redirected immediately to this timely, important video.

Dr. Craig Erickson presenting on the topic of EEG biomarkers at the 2018 International Fragile X Conference in CincinattiDrs. Craig Erickson and Devin Binder present recent EEG data, including treatment data, in both patients with Fragile X syndrome and in mouse models of the disease.

The congruence of certain EEG findings across humans and mice stimulates the goal of validation of EEG parameters as translational biomarkers for treatment development. In this video presentation, Erickson and Binder summarize recent findings, current and ongoing efforts, and the future direction for this work, which they hope will lead to more objective, measurable parameters to quantify treatment effects on brain circuits in Fragile X syndrome.

Presented by

  • Craig Erickson, M.D., Clinic Director, Cincinnati Fragile X Research and Treatment Center
  • Devin K. Binder, M.D., Ph.D., Associate Professor in Residence, Department of Biomedical Sciences, University of California, Riverside

Get the Video!